Form 4: Replimune Group Director, Kapil Dhingra, Acquires Stock Options
SEC Form 4 Filing
Director Kapil Dhingra acquired stock options in Replimune Group, Inc. exercisable for 32,000 shares of common stock.
Summary
- Kapil Dhingra, a director of Replimune Group, Inc., reported a transaction involving derivative securities.
- On April 1, 2025, Dhingra acquired stock options for 32,000 shares of Replimune Group's common stock at an exercise price of $8.40.
- The options vest entirely on April 1, 2026, and expire on April 1, 2035.
- Following the transaction, Dhingra directly owns options exercisable for 32,000 shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.
Industry Context
This is a standard disclosure related to insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.
Stakeholder Impact
- The transaction could signal confidence in the company's future prospects to shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of transaction: acquisition of stock options. |
| 04/01/2026 | Vesting date for the stock options. |
| 04/01/2035 | Expiration date for the stock options. |
| 04/03/2025 | Date of Form 4 filing. |
Keywords
Replimune Group, Dhingra, Stock Options, Form 4, Director, REPL, Beneficial Ownership, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.